Press Releases

BOSTON and SYDNEY — 18 May 2017 — GI Dynamics®, Inc. (ASX: GID) (the Company) will hold its 2017 Annual Meeting of Stockholders on 22 May 2017, at 6:00 p.m., United States Eastern Daylight Time, (23 May 2017, at 8:00 a.m., Australian Eastern Standard Time) at the offices of Mintz, Levin, Cohn,...

BOSTON and SYDNEY — 18 May 2017 — GI Dynamics®, Inc. (ASX:GID) today announced that it received notification from its notified body SGS United Kingdom Limited (SGS) that the CE Mark for its EndoBarrier® system has been suspended pending closure of nonconformances related to its quality management...

BOSTON and SYDNEY — 8 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, has announced additional members of the GI Dynamics Scientific Advisory Board...

BOSTON and SYDNEY — 4 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced that new EndoBarrier data will be presented at Digestive Disease Week®...

BOSTON and SYDNEY — 3 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces Allenby Capital Limited’s engagement to explore options for seeking...

BOSTON and SYDNEY – 23 March 2017 – GI Dynamics, Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe and the Middle East for patients with type 2 diabetes and obesity, announced that it will release its 2016 Annual Report on Form 10K on or before 31 March EDT |...

BOSTON and SYDNEY — 13 March 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced additional members of the GI Dynamics Scientific Advisory Board...

BOSTON and SYDNEY — 7 March 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced the creation of the GI Dynamics Scientific Advisory Board (SAB).  The...

First study of EndoBarrier in adolescents completed at University Children’s Hospital (UCH) in Ljubljana, Slovenia Preliminary data show BMI reduced by 10 percent Acceptable safety profile and improvement in metabolic parameters BOSTON and SYDNEY — 16 February 2017 — GI Dynamics, Inc. (ASX:GID), a...

FOR IMMEDIATE RELEASE BOSTON and SYDNEY — 1 February 2017 — GI Dynamics, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier in Europe for patients with type 2 diabetes and obesity, announces that InEk, the German Institute for the Hospital Remuneration System, has...